Dyadic International, Inc. Stock Other OTC
Equities
US26745T1016
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.67 USD | -52.96% | +5.59% | +79.89% |
05-14 | Transcript : Dyadic International, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | Earnings Flash (DYAI) DYADIC INTERNATIONAL Posts Q1 Revenue $334.6M | MT |
Sales 2024 * | 3.5M 4.76M | Sales 2025 * | 6.1M 8.3M | Capitalization | 45.9M 62.47M |
---|---|---|---|---|---|
Net income 2024 * | -8M -10.89M | Net income 2025 * | -11M -14.97M | EV / Sales 2024 * | 13.1 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.52 x |
P/E ratio 2024 * |
-2.38
x | P/E ratio 2025 * |
-4.91
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.04% |
Latest transcript on Dyadic International, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Mark Emalfarb
FOU | Founder | 69 | 78-12-31 |
Ping Rawson
DFI | Director of Finance/CFO | 48 | 16-05-31 |
Joseph Hazelton
COO | Chief Operating Officer | 48 | 21-11-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Emalfarb
FOU | Founder | 69 | 78-12-31 |
Jack Kaye
BRD | Director/Board Member | 80 | 15-04-30 |
Michael Tarnok
BRD | Director/Board Member | 69 | 14-06-11 |
1st Jan change | Capi. | |
---|---|---|
+33.07% | 49.46B | |
+2.08% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+12.08% | 26.61B | |
-22.56% | 18.64B | |
+8.43% | 13.16B | |
+30.32% | 12.55B | |
+24.00% | 12.1B |